| Dr Anjanette Laurice Mcilwain-mccollum, MD | |
|
6387 Ramsey St, Suite 240, Fayetteville, NC 28311-9441 | |
| (910) 615-3960 | |
| (910) 486-2159 |
| Full Name | Dr Anjanette Laurice Mcilwain-mccollum |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 6387 Ramsey St, Fayetteville, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164405189 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 200200411 (North Carolina) | Primary |
| Entity Name | Hoke Healthcare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114277035 PECOS PAC ID: 1153569405 Enrollment ID: O20130529000286 |
News Archive
A team of ear, nose, and throat specialists has demonstrated that eating honey after swallowing a button battery has the potential to reduce serious injuries in small children.
Drug makers Bayer AG and Johnson & Johnson's new blood clot preventing drug can provide life-saving benefits at very low doses in patients who suffer from acute coronary syndrome finds a new clinical trial.
Vigil Health Solutions Inc. ("Vigil") (TSX VENTURE:VGL) is pleased to announce the completion of its 2009 AGM. Shareholders elected Greg Peet (as Chairman), Troy Griffiths, Harry Jaako, Stephen Martin and Tanner Philp as Directors of Vigil. KPMG LLP was appointed auditors of Vigil. The shareholders also approved an amendment to the Omnibus Plan to increase the number of Common Shares reserved for issuance under the Omnibus Plan to 15,000,000 Common Shares (being approximately 15.0% of the total outstanding Common Shares of the Company).
Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13).
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anjanette Laurice Mcilwain-mccollum, MD 6387 Ramsey St, Suite 240, Fayetteville, NC 28311-9441 Ph: (910) 615-3960 | Dr Anjanette Laurice Mcilwain-mccollum, MD 6387 Ramsey St, Suite 240, Fayetteville, NC 28311-9441 Ph: (910) 615-3960 |
News Archive
A team of ear, nose, and throat specialists has demonstrated that eating honey after swallowing a button battery has the potential to reduce serious injuries in small children.
Drug makers Bayer AG and Johnson & Johnson's new blood clot preventing drug can provide life-saving benefits at very low doses in patients who suffer from acute coronary syndrome finds a new clinical trial.
Vigil Health Solutions Inc. ("Vigil") (TSX VENTURE:VGL) is pleased to announce the completion of its 2009 AGM. Shareholders elected Greg Peet (as Chairman), Troy Griffiths, Harry Jaako, Stephen Martin and Tanner Philp as Directors of Vigil. KPMG LLP was appointed auditors of Vigil. The shareholders also approved an amendment to the Omnibus Plan to increase the number of Common Shares reserved for issuance under the Omnibus Plan to 15,000,000 Common Shares (being approximately 15.0% of the total outstanding Common Shares of the Company).
Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13).
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to commence a pivotal, CE Mark registration trial for BL-5010P, for the non-surgical removal of benign skin lesions.
› Verified 4 days ago
Dr. Barbara Lynn Appel, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2035 Valleygate Drive, Ste 101, Fayetteville, NC 28304 Phone: 910-484-8009 Fax: 910-484-2005 | |
Mrs. Holly Mallett Richter, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 538 Sandhurst Dr, Fayetteville, NC 28304 Phone: 910-321-7337 Fax: 910-321-0003 | |
Dr. Rita Louise Gunter, M.D Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 227 Fountainhead Lane, Fayetteville, NC 28301 Phone: 910-433-3600 Fax: 910-321-7102 | |
Horace Robert Long, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1606 Morganton Rd, Fayetteville, NC 28305 Phone: 910-484-3121 Fax: 910-484-9027 | |
Dr. Issa Elgendy, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1262 Oliver St, Ste B, Fayetteville, NC 28304 Phone: 910-609-4801 Fax: 910-609-5406 | |
Edwin B Robins, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1638 Owen Drive, Fayetteville, NC 28304 Phone: 910-609-4000 |